Study guide

3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

Key Takeaways Explain This Topic AI

An environmental excursion occurs when viable air, surface or particle results exceed USP action levels or ISO limits. Facility SOPs may add their own triggers, such as objectionable organisms.

When air or surface action levels are exceeded, USP <797> requires an attempt to identify the organism to genus (with a microbiologist's help), an investigation, and documented corrective action based on both the count and the organism.

The 2008 chapter required immediate remediation of highly pathogenic organisms regardless of count. Today that is a common SOP rule rather than a USP requirement, and USP instead requires regular trend review with personnel data.

Remediation includes root cause analysis, cleaning plus disinfection plus sporicidal treatment, retraining where warranted, re-sampling to confirm the action worked, and a risk review of CSPs made during the affected period.

Last updated: September 2026

Definition of an Environmental Excursion

An environmental excursion is an out-of-specification (OOS) event indicating a loss of environmental control. Under USP <797>, an excursion is triggered when:

Non-viable particle concentrations exceed ISO 14644-1 limits during dynamic testing.

Viable air CFU counts exceed action levels (> 1 in ISO 5, > 10 in ISO 7, > 100 in ISO 8).

Surface microbial CFU counts exceed action levels (> 3 in ISO 5, > 5 in ISO 7, > 50 in ISO 8).

A facility-defined trigger is met. For example, an SOP may treat any recovery of an organism it lists as objectionable as an excursion. The current chapter does not require this, but the 2008 chapter did, and many facilities kept the rule.

Microbial Identification Requirements

When an air or surface result exceeds its action level , USP <797> requires an attempt to identify the recovered organisms to the genus level , with a microbiologist's help. The corrective action plan must depend on both the count and the organism. Identification below the action level is not required, but it is valuable in any investigation.

Why Genus Identification Matters

Knowing whether an organism is Bacillus , Staphylococcus , Pseudomonas , or Aspergillus provides vital forensic intelligence regarding the source of contamination:

Human Source (e.g., Staphylococcus epidermidis , Micrococcus luteus ): Points directly to improper garbing, exposed skin, poor hand hygiene, or personnel touch contamination.

Water/Plumbing Source (e.g., Pseudomonas aeruginosa , Burkholderia cepacia , Serratia marcescens ): Points to sink splashback, stagnant drain traps, leaking HVAC coils, or wet mops.

Environmental/Airborne Spore Source (e.g., Bacillus species, Aspergillus , Penicillium ): Points to cardboard introduction, unsealed construction, damaged HEPA filters, or failure to apply sporicidal disinfectants.

Objectionable and Highly Pathogenic Organisms

Many facility SOPs treat recovery of Gram-negative bacilli, coagulase-positive staphylococci ( Staphylococcus aureus ), or any mold or yeast as objectionable regardless of count, which carries forward the 2008 chapter's rule. Typical SOP responses are stopping compounding in the affected area, a formal CAPA, and notifying clinicians if CSPs made during the period were distributed.

  • Step-by-Step Excursion Remediation Workflow [Excursion Identified]
  • │
  • ▼
  • [1. Immediate Containment] ──► Quarantine affected PEC / Halt compounding
  • │
  • ▼
  • [2. Microbial Identification] ──► Identify to genus level; assess pathogenicity
  • │
  • ▼
  • [3. Root Cause Analysis] ──► Evaluate HVAC, cleaning logs, personnel, materials
  • │
  • ▼
  • [4. Comprehensive Remediation] ──► Triple cleaning with sporicidal disinfectant
  • │
  • ▼
  • [5. Re-Sampling] ──► Active air & surface sampling under dynamic conditions
  • │
  • ▼
  • [6. Retrospective Risk Evaluation] ──► Evaluate integrity of CSPs made in window
  • Comprehensive Cleaning and Disinfection Protocol

Remediation of an excursion requires a rigorous triple-cleaning decontamination protocol :

Detergent Cleaning : Wash all surfaces with a sterile neutral detergent and purified water to strip organic biofilms and particulate soils.

Disinfection : Apply a sterile EPA-registered disinfectant (e.g., quaternary ammonium compound or phenolic) with verified contact time.

Sporicidal Application : Saturate all walls, ceilings, fixtures, and PEC interiors with a sterile sporicidal agent (e.g., hydrogen peroxide/peracetic acid blend or sodium hypochlorite) for the full manufacturer-mandated dwell time.

Sterile 70% IPA Rinse : Remove corrosive or sticky chemical residues from stainless steel surfaces.

Retrospective Patient Risk Evaluation

The Designated Person must evaluate all CSPs prepared during the excursion window (from the date of sampling until identification of the excursion). If high-risk or pathogenic organisms were present, the pharmacy must immediately initiate product quarantine, evaluate patient recall protocols, and notify clinical providers of potential microbial exposure.

Clearance Criteria and Dynamic Re-sampling

Compounding operations cannot resume simply because cleaning was completed. Formal facility clearance requires documented dynamic re-sampling:

Environmental Stabilization : The HVAC system must run continuously for several hours after cleaning to purge chemical vapors and re-establish pressure cascades.

Dynamic Re-sampling Protocol : Technicians execute comprehensive viable active air sampling, total non-viable particle counts, and surface contact plate sampling under simulated dynamic compounding conditions.

Clearance Benchmarks : All sample locations must yield zero objectionable organisms, and all numerical CFU and non-viable particle counts must fall comfortably below pharmacopeial action levels.

Formal Sign-off : The Designated Person must review the complete CAPA investigation package, verify microbiological laboratory clearance reports, and execute a formal written release before any patient compounding resumes.

Statistical Trend Analysis and Quality Assurance Control Charting

Modern quality systems do not wait for an action-level breach to occur. USP <797> requires regular review of sampling data to detect trends , together with personnel data such as training records, observations and competency results. Facilities utilize Statistical Process Control (SPC) tools, such as Shewhart control charts and cumulative sum (CUSUM) analyses, to evaluate bioburden trajectory over time.

Establishing Alert Levels

Action levels are defined by USP <797>. The chapter does not set alert levels , but USP <1116> describes them, and many facilities set their own (typically set at 50 % 50\% 50% of the regulatory action level or based on 2 standard deviations above baseline bioburden):

ISO Class 7 Surface Alert Level : ≥ 3 CFU \ge 3\,\text{CFU} ≥ 3 CFU (triggers internal sanitization review before reaching the action level of > 5 CFU > 5\,\text{CFU} > 5 CFU ).

ISO Class 8 Surface Alert Level : ≥ 25 CFU \ge 25\,\text{CFU} ≥ 25 CFU (triggers gowning audit before breaching > 50 CFU > 50\,\text{CFU} > 50 CFU ).

Identifying Adverse Patterns

A trend is defined by:

Three consecutive sampling events demonstrating a steady upward drift in CFU counts, even if all results remain below official action levels.

Repeated recovery of the same microbial genus (e.g., recurring Micrococcus or Bacillus ) over multiple cycles, indicating persistent biofilm formation or ineffective sanitizers.

Seasonal bioburden spikes: Tracking seasonal transitions enables compounding leadership to proactively increase sporicidal application frequencies and replace HVAC intake pre-filters before cleanroom excursions compromise sterile compounding safety.